Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
diclofenac epolamine + heparin
- Development stage
- Unknown
- Lead developer
- IBSA
- Modality
- Small Molecules
- Administration
- Topical, Transdermal
01
Overview
Flectoparin Tissugel is a topical medicated plaster (transdermal patch) developed by IBSA Institut Biochimique SA for the local treatment of musculoskeletal pain and inflammation. It contains a combination of diclofenac epolamine (DHEP), a non-steroidal anti-inflammatory drug (NSAID), and heparin, a sulfated glycosaminoglycan. Diclofenac provides analgesic and anti-inflammatory effects by inhibiting cyclooxygenase (COX) enzymes and reducing prostaglandin biosynthesis. Heparin acts as an anticoagulant and anti-edematous agent, helping to reduce bruising and swelling at the site of injury. The product is specifically indicated for conditions such as sprains, strains, and contusions accompanied by hematoma or edema.
- Brand names
- Flectoparin TissugelFlectoparinFlectorTissugelHéparine
- Other names
- DHEP-heparin plasterdiclofenac hydroxyethylpyrrolidine and heparin plaster
02
Targets
ATIII (Antithrombin III)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on diclofenac epolamine + heparin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on diclofenac epolamine + heparin.